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Purpose: To investigate whether serum levels of soluble Fas (sFas) and interleukin-6 (IL-6) 
could function as an index of the efﬁ  cacy of steroid pulse treatment, we examined the serum 
level of these proteins before and after steroid pulse treatment in thyroid-associated ophthal-
mopathy patients.
Methods: We gathered the blood of thyroid-associated ophthalmopathy patients before or 
after steroid pulse treatment, obtained serum with a centrifuge, and measured the serum levels 
of sFas and IL-6 by enzyme-linked immunosorbent assay (ELISA).
Results: There was no difference in serum IL-6 value between pre- and poststeroid pulse treat-
ment. Serum sFas value was signiﬁ  cantly decreased in both pre- and poststeroid pulse treatment. 
Furthermore, there was a recognizable improvement in the degree of the extraocular muscle 
thickening after treatment in cases in whom the serum sFas value was lower than 3 ng/ml prior 
to the beginning of the therapy. In patients who had a serum sFas value of more than 3 ng/ml, 
there was no improvement in the degree of thickening of the extraocular muscle.
Conclusions: Serum level of sFas is an accurate index of the outcome of steroid pulse treatment 
in thyroid-associated ophthalmopathy and may become a useful index to gauge the status of 
convalescence.
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Introduction
Thyroid-associated ophthalmopathy is an autoimmune disease characterized by 
exophthalmos, increment of intraocular pressure, lid swelling, visual ﬁ  eld loss, and 
diplopia. These symptoms appear with hyperthyroidism, however they are not, with 
the exception of the latter, always recognized. Sato demonstrated a cross section of 
the extraocular muscle in computed tomography, and reported a method to judge the 
effect of steroid pulse treatment of thyroid associated ophthalmopathy (Kenji et al 
2003). Most of the reports indicate that there is no hematologically curative effect for 
this disease. However the fact that levels of soluble Fas (sFas) and interleukin-6 (IL-6) 
were reported to be extremely high in thyroid-associated ophthalmopathy (Siddiqi 
et al 1999; van Lopik et al 1999), led us to speculate whether they could function as 
markers for the curative effect of therapy for this autoimmune disease.
Patients and methods
Thirty-one hospitalized patients (11 men and 20 women) suffering from thyroid-
associated ophthalmopathy were examined at Sapporo Medical University Hospital 
between December, 1999 and January, 2000. The mean age of the patients was 48.67 
years (range, 22 to 62), men 54 years (range, 41 to 62) and women 45.7 (range, 22 
to 62). Patients were admitted to hospital on the basis of a clinical activity score Clinical Ophthalmology 2008:2(3) 610
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of 4 or more, or diplopia, or deterioration in visual acuity 
within the previous three months (Heufelder and Joba 
2000). The treatment was as follows; 1000 mg intravenous 
methylprednisolone each day for four days and thereafter 
30 mg administration of prednisolone each day for three 
days performed as 1 unit. The patients received 3 units 
in total. We obtained informed consent from the patients 
for preparation of the plasma samples before and after 
steroid pulse treatment. The serum was divided and used 
for each measurement of sFas and IL -6. The serum levels 
of sFas and IL-6 were measured with an SFAS enzyme-
linked immunosorbent assay (ELISA) kit purchased from 
MBL company (Nagoya, Japan) and an IL-6 ELISA kit 
purchased from Dainippon Pharmaceutical Corporation, 
respectively. Each value was measured at an absorbance 
(vice-wavelength 620 nm) of 450 nm with an automatic 
spectrophotometer. We examined the degree of extraocular 
muscle thickness by a coronal 2 mm section the computed 
tomography (Aquilion, Toshiba Medical System, Japan) at 
pre- and poststeroid pulse treatment. The area of the greatest 
thickening of the selected extraocular muscle was used to 
assess the effect of steroid pulse treatment.
Results
Figure 1 shows the maximum area of the extraocular muscle 
of each patient at before and after steroid pulse treatment. The 
extent of the extraocular muscle had decreased after treatment in 
comparison with before therapy. The difference in the degree of 
thickness of the extraocular muscle subsequent to treatment was 
statistically signiﬁ  cant (p  0.001). Before treatment, the serum 
level of sFas was 2.4 ± 0.9 ng/ml, whereas after treatment it was 
2.1 ± 0.9 ng/ml. The serum level of sFas revealed a signiﬁ  cant 
difference between before and after treatment (p  0.01). 
The serum level of IL-6 was 20.2 ± 11.1 pg/ml after treatment, 
however the value before treatment was 17.3 ± 6.9 pg/ml, indi-
cating no signiﬁ  cant difference. The changes in serum level of 
sFas in each patient are shown in Figure 3. As can be seen, after 
the therapy there were two groups of patients: those exhibiting 
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Figure 1 This shows the degree of extraocular muscle thickening in coronal 
slice pre- and poststeroid pulse treatment.
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Figure 2   We gathered serum from pre- and poststeroid pulse treatment patients and 
measured sFas /IL-6. A shows the changes in sFas value. Student t-test revealed the 
value of sFas to be signiﬁ  cantly decreased following steroid pulse treatment (student 
t test, p  0.01). B shows the changes in IL-6. IL-6 did not decrease in either pre- or 
poststeroid pulse treatment.
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Figure 3 This shows the serum level of sFas before and after steroid pulse treatment.Clinical Ophthalmology 2008:2(3) 611
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changed serum levels of sFas and those showing no change. 
Patients with a high level of sFas prior to treatment tended to 
have a similarly high level even after steroid pulse treatment. 
Two categories of sFas values were disclosed, a high value 
group in both pre- and poststeroid pulse treatment and another 
one (Figure 2A). A decrease in sFas value was recognized 
after steroid pulse treatment in the patients who had a low sFas 
value before steroid pulse treatment, whereas patients with a 
high level maintained this level after steroid pulse treatment. 
Figure 4 shows the relationship between improvement in the 
degree of thickening of the extraocular muscle and sFas at 
pre- and poststeroid pulse treatment. In cases in whom sFas 
level was less than 3 ng/ml before steroid pulse treatment, the 
average width of the cross section of extraocular muscle was 
45.6 ± 19.9 mm2, and in cases in whom sFas level was more 
than 3 ng/ml this average cross-section was 49.41 ± 31.01 mm2. 
As shown in Figure 4A, no signiﬁ  cant difference was found in 
the width of the cross-sectional area of the extraocular muscle 
between these 2 groups. A comparison of the more than 3 ng/ml 
and less than 3 ng/ml sFas groups in terms of improvement 
in the degree of the extraocular muscle thickness revealed an 
average of 17.7 ± 19.2 mm2 and 0.7 ± 14.4 mm2 for the width of 
the cross-sectional area of the extraocular muscle, respectively 
(Figure 4B). This represented a signiﬁ  cant improvement in the 
low level sFas group by steroid pulse treatment (p  0.001). 
The value of IL-6 increased in only 2 subjects after treatment, 
and in all the other subjects there were hardly any changes at 
all (Figure 2B).
Discussion
A rise in IL-6 due to autoimmune disease has been reported 
(Uysal et al 1999). The increase of IL-6 can lead to a pro-
liferation of hemaocytes, immunoresponse, inﬂ  ammatory 
reaction, and an increase in the number of cells in the nervous 
system. In thyroid-associated ophthalmopathy, accumulation 
of glycosaminoglycan to orbital adipose tissue and connec-
tive tissue of the extraocular muscle is seen by histopathology 
along with lymphocyte permeation to the tissues (Prophet 
et al 2001), and there are some reports of a rise in the serum 
level of IL-6 at the same time (Wakelkamp et al 2000; Kozora 
et al 2001). IL-6 production can be controlled by steroid 
treatment. The fact that IL-6 is associated etiologically with 
thyroid-associated ophthalmopathy (Siddiqi et al 1999). It 
means that measurement of IL-6 is useful for the treatment 
of this disease (Wakelkamp et al 2000). However, in our 
experiment, since serum IL-6 level hardly changed after 
steroid pulse treatment, except in two cases, it appears that 
its use as a marker for the curative effect of steroid pulse 
treatment in thyroid-associated opthalmopathy is dubious. 
sFas is thought to be produced as a result of a living body 
protective reaction against apoptosis in Fas/sFas (Cheng et al 
1994). Ohtsuka reported a normal control serum level of sFas 
was 0.93 (SD 0.32) ng/ml, and a the high level of sFas in 
the extraocular muscle thickening group of his study and an 
association between extraocular muscle disorder and sFas 
was suggested (Ohtsuka and Hashimoto 2000). In our study, 
a serum level of sFas of less than 3 ng/ml and a decrease in 
sFas value after steroid pulse treatment was indicative of 
a signiﬁ  cant improvement in the degree of thickening of 
the extraocular muscle. When sFas was over 3 ng/ml after 
treatment, improvement in the degree of thickening of the 
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Figure 4 A shows the cross-section area of extraocular muscle before steroid pulse 
treatment. No signiﬁ  cant difference in the cross-section area of extraocular muscle was 
observed between subjects with sFas levels of less than 3 ng/ml and those with more 
than 3 ng/ml. B shows those with sFas level of less than 3 ng/ml after steroid pulse treat-
ment disclosed improvement in extraocular muscle thickness (Man-Whitney’s U test).
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extraocular muscle did not occur, even though steroid pulse 
treatment had been performed. Our results suggest that the 
pretreatment level could be useful as a predictive parameter 
of the curative response to the steroid pulse therapy for thy-
roid-associated ophthalmopathy.
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